A multi-institution team identified a novel immune evasion mechanism in acute myeloid leukemia centered on the glycoprotein CD43, described as a “don’t eat me” signal. The research, published in Science, ties CD43 biology to how AML cells avoid immune-mediated clearance. The investigators include Mass General Brigham, Dana-Farber Cancer Institute, and the Broad Institute of MIT and Harvard, linking mechanistic discovery to translational potential for checkpoint-like interventions beyond traditional pathways. By locating a specific surface signal responsible for immune escape, the study provides a candidate target for therapies aiming to improve the effectiveness of existing or next-generation immunotherapy regimens in AML. For biotech teams, the finding increases attention on antigen and immune-evasion biology as levers for combination design and patient stratification.